| Similar Articles |
|---|
 |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.   |
The Motley Fool
June 11, 2010
Brian Orelli |
Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp. |
The Motley Fool
January 5, 2010
Brian Orelli |
Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix. |
The Motley Fool
March 22, 2010
Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio. |
BusinessWeek
December 10, 2009
Weintraub & Wechsler |
The New Prominence of Comparative Drug Trials Pharmaceutical makers, once wary of head-to-head trials, now embrace them as marketing tools. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
The Motley Fool
July 27, 2010
Brian Orelli |
Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant. |
BusinessWeek
June 2, 2011
Kresge & Connolly |
A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies. |
The Motley Fool
January 20, 2011
Brian Orelli |
Merck's Bleeding Out Vorapaxar caused it. |
The Motley Fool
May 11, 2009
Brian Orelli |
Brilliant, Now Let's See the Data AstraZeneca's investors today should be cautiously optimistic about Brilinta. It could be a blockbuster for the company, but it may need some brilliant marketing to compete. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
December 14, 2010
Brian Orelli |
Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold. |
The Motley Fool
August 26, 2010
Brian Orelli |
Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
BusinessWeek
February 26, 2007
Arlene Weintraub |
The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target. |
The Motley Fool
January 31, 2011
Brian Orelli |
Better Buy: Amarin or Clinical Data? A battle of the takeover targets. |
The Motley Fool
September 20, 2010
Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Most Interesting FDA Review for 2008 Eli Lilly preps for an upcoming FDA review of its top pipeline drug, the blood thinner prasugrel. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
December 23, 2009
Brian Orelli |
2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
June 9, 2010
Brian Orelli |
The Drug Passed, but the Stock Fell? Regeneron only bats .500. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
January 14, 2011
Brian Orelli |
Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
January 28, 2011
Brian Orelli |
Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff. |
The Motley Fool
August 4, 2010
Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. |
The Motley Fool
July 29, 2010
Brian Orelli |
This FDA Panel Isn't Brilliant Why does AstraZeneca's blood thinner Brilinta work better outside the U.S. than here at home? The Food and Drug Administration's advisory panel didn't seem to have a good explanation, but they didn't appear to care much, either. |
BusinessWeek
February 25, 2010
Weintraub & Tirrell |
Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed. |
The Motley Fool
March 15, 2010
Brian Orelli |
Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
The Motley Fool
June 25, 2008
Brian Lawler |
Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
July 16, 2010
Brian Orelli |
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year. |
The Motley Fool
August 31, 2009
Brian Orelli |
Thinning Out Plavix's Monopoly Until now sanofi-aventis' and Bristol-Myers Squibb's Plavix didn't have a monopoly on the blood-thinning market, but it was pretty darn close. But now, another competitor's on the way. |
The Motley Fool
January 13, 2011
Brian Orelli |
FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
September 27, 2010
Brian Orelli |
Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit. |
The Motley Fool
October 5, 2010
Andrew Bond |
Wal-Mart Enters the Health-Care Fray Wal-Mart and Humana's partnership will have competitors scrambling. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
October 22, 2007
Brian Lawler |
Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
